Searched for
MSD MERCK
Stocks in news: Rajesh Exports, Lenskart, Suzlon Energy, Aurobindo Pharma, Tata MotorsIndian markets saw volatility and closed lower on Wednesday. Key companies are in focus due to significant developments. SoftBank reduced i...- Aurobindo Pharma enters biologics contract manufacturing with Rs 1,200-crore Telangana facilityAurobindo Pharma has launched TheraNym, a major biologics manufacturing plant in Telangana. This facility will produce biologic medicines f...
- Sun Pharma shares jump over 9% after firm announces $12 billion Organon acquisitionSun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...
- MSD to sign licensing pacts with 5 Indian drug firms for oral drug candidate for COVID-19MSD has decided to enter into non-exclusive voluntary licensing agreements for molnupiravir with five established Indian generic manufactur...
- Zydus Cadila acquires six brands from Merck IndiaThe acquired brands Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten range had clocked sales of Rs 840 million in 2015.
- Merck's Indian unit MSD may sell primary care drugs to focus on core brandsA sizeable part of the divestiture is from the primary care segment with a few Indian drug makers showing interest. Valuation is, however, ...
- Hilleman Lab scouts for partners to develop low cost vaccinesHilleman said it is looking to tie up with vaccine specialty companies and government agencies to fund a Rs 300 project for developing some...
- Hilleman Lab to invest Rs 300 crore to develop vaccines"We are spending around Rs 300 crore over the next 4-5 years to develop low-cost vaccines. We are developing vaccines to treat rotavirus, c...
- MSD India to invest $10 million to reduce maternal mortalityMSD for Mothers, drug firm would partner three non-governmental organisations across three states in India- Rajasthan, Jharkhand and Uttar ...
- No interim relief to Merck against Glenmark’s diabetes genericsDelhi High Court has refused to bar Glenmark from selling the generic versions of anti-diabetic drugs manufactured by Merck Sharp & Dohme.
- Merck scouts for marketing, licensing pacts with Indian cosMerck & Co, is looking at in-licensing and co-marketing arrangements with Indian pharma cos as it wants to realise its ambitions to become ...
- Hilleman Lab to invest about Rs 650 cr to develop vaccinesAs per the company's estimates, it will take 2-4 years in research and development activities to come out with the new vaccine.
- Merck, Ranbaxy drug development deal called offUS drug maker Merck & Co has terminated its nearly two-year-old alliance with Ranbaxy Laboratories to develop anti-infective medicines, whi...
- Relocation triggers exits at Merck armAround 50 executives quit MSD, the Indian arm of Merck & Co, in the past few months — most opted out due to the company’s decision to reloc...
- Merck arm to sell cheap diabetes drugThis is perhaps one of the few instances where a drug is cheaper in India, as against its price in other developed markets. (Januvia is pri...
- Merck buys Schering-Plough in $41.1b cash-&-stock dealUS-based Merck & Co is acquiring Schering-Plough for $41.1 billion in a cash-and-stock deal, to create a $47 billion drug major.
- Merck buys Schering-Plough for $41 bn to access new drugsUS-based Merck & Co on Monday said it is acquiring Schering Plough for $41.1 bn in a cash-and-stock deal to create a $42-bn drug major.
- Merck subsidiary plans to launch patented drugsMerck Sharp & Dohme (MSD) Pharmaceuticals is betting big on India, an emerging market for its patented and first research-based vaccines an...
- MSD Pharma launches JANUVIA for diabetic careDrug firm MSD Pharmaceuticals today launched its patent medicine under the brand name 'JANUVIA' in diabetic care segment and aims to tap fo...
- US-based Merck to double workforce by year-endUS-based $25-billion Merck also plans to launch drugs targeted to Indian patients and introduce a competitive pricing pattern.
Load More
